Abstract
Gene therapy continues to grow as an emerging treatment strategy toward numerous diseases. However, such prospects are hindered by the use of viral vectors prompting significant safety concerns along with limitations concerning repeat administrations, size of delivered gene construct, scale-up, high production costs, contamination during production, and lack of desired tissue selectivity. Non-viral gene delivery demonstrates the potential to address the abovementioned limitations, but itself generally suffers from low efficacy. Continuing efforts have been made to develop innovative delivery systems, synthetic gene carriers, and DNA vectors in a concerted attempt to enhance gene delivery suitable for clinical applications. In this review, we focus on the advances in the design of novel DNA vectors catered to enhance transfection and transgene expression and their influences on the efficacy and safety of existing and emerging delivery systems and synthetic vectors for non viral gene delivery.
Keywords: Cationic lipids, gene therapy, linear covalently closed (LCC) DNA minivector, lipoplex, non-viral gene delivery, recombinant plasmid DNA vectors, synthetic vectors.
Current Gene Therapy
Title:Impact of DNA Vector Topology on Non-Viral Gene Therapeutic Safety and Efficacy
Volume: 14 Issue: 4
Author(s): Chi H. Sum, Shawn Wettig and Roderick A. Slavcev
Affiliation:
Keywords: Cationic lipids, gene therapy, linear covalently closed (LCC) DNA minivector, lipoplex, non-viral gene delivery, recombinant plasmid DNA vectors, synthetic vectors.
Abstract: Gene therapy continues to grow as an emerging treatment strategy toward numerous diseases. However, such prospects are hindered by the use of viral vectors prompting significant safety concerns along with limitations concerning repeat administrations, size of delivered gene construct, scale-up, high production costs, contamination during production, and lack of desired tissue selectivity. Non-viral gene delivery demonstrates the potential to address the abovementioned limitations, but itself generally suffers from low efficacy. Continuing efforts have been made to develop innovative delivery systems, synthetic gene carriers, and DNA vectors in a concerted attempt to enhance gene delivery suitable for clinical applications. In this review, we focus on the advances in the design of novel DNA vectors catered to enhance transfection and transgene expression and their influences on the efficacy and safety of existing and emerging delivery systems and synthetic vectors for non viral gene delivery.
Export Options
About this article
Cite this article as:
Sum H. Chi, Wettig Shawn and Slavcev A. Roderick, Impact of DNA Vector Topology on Non-Viral Gene Therapeutic Safety and Efficacy, Current Gene Therapy 2014; 14 (4) . https://dx.doi.org/10.2174/1566523214666140612154929
DOI https://dx.doi.org/10.2174/1566523214666140612154929 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Towards a Personalised Approach to Managing Influenza Infections in Infants and Children – Food for Thought and a Note on Oseltamivir
Infectious Disorders - Drug Targets Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Effects of Physical Exercise on Depressive Symptoms and Biomarkers in Depression
CNS & Neurological Disorders - Drug Targets Hypericin Lights Up the Way for the Potential Treatment of Nasopharyngeal Cancer by Photodynamic Therapy
Current Clinical Pharmacology Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis
Current Pharmaceutical Design Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years
Recent Patents on Anti-Cancer Drug Discovery An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Does Ligand Symmetry Play a Role in the Stabilization of DNA G-Quadruplex Host-Guest Complexes?
Current Medicinal Chemistry Microtubules in Apoptosis Induction: Are They Necessary?
Current Cancer Drug Targets Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management
Current Medicinal Chemistry Innovative Drug Delivery Systems for the Administration of Natural Compounds
Current Bioactive Compounds Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry